Compare Herbalife Nutrition Ltd (HLF) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Illumina, Inc. — how do they compare? Herbalife Nutrition Ltd trades at $12.06 (market cap $1.27B), while Illumina, Inc. trades at $190.65 (market cap $27.94B). The key difference: Illumina, Inc. is far larger — about 22× Herbalife Nutrition Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals.
| HLF | ILMN | |
|---|---|---|
Market Cap | $1.27B | $27.94B |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $194.33 |
52-Week Low | $7.75 | $91.00 |
Enterprise Value | $3.00B | $29.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.25, up 2.17% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.64, beating expectations, and raised full-year guidance. Revenue remains stable around $5 billion annually, with a net income margin of 4.66%. Valuation ratios appear attractive with a P/E of 5.26 and P/S of 0.25. Debt-to-asset ratio improved to 71.67% in 2025, reflecting progress in deleveraging.
The outlook is mixed: strong analyst support (57.69% buy ratings) and operational improvements contrast with high debt levels and negative shareholder equity. Key risks include competitive pressures and reliance on international growth. Near-term catalyst is Q2 2026 earnings on August 5, 2026.
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
